Trials / Completed
CompletedNCT00887809
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Phase II Trial Of Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test whether an experimental drug called bevacizumab given together with gemcitabine and docetaxel, a standard chemotherapy regimen for sarcoma, can help sarcoma patients. This trial will examine what effects, good and/or bad the combination of gemcitabine, docetaxel and bevacizumab has on sarcoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | gemcitabine | |
| DRUG | docetaxel | |
| DRUG | bevacizumab |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2014-10-01
- Completion
- 2014-11-01
- First posted
- 2009-04-24
- Last updated
- 2016-01-25
- Results posted
- 2016-01-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00887809. Inclusion in this directory is not an endorsement.